Peer reviewed
Tirzepatide and Semaglutide for Obesity in Adults (SURMOUNT-5)
Head-to-head Phase 3 trial (Garvey et al., 2024) directly comparing tirzepatide and semaglutide for weight loss in adults with obesity. Reported greater mean weight loss with tirzepatide (approximately 20.9%) than semaglutide (approximately 17.3%) at 72 weeks.
New England Journal of MedicinePublished 2024-12-04Accessed 2026-07-08
Registry record
Source metadata
- Publisher
- New England Journal of Medicine
- Source type
- Peer reviewed
- Registry ID
nejm-tirzepatide-surmount5-2024
Source usage
Linked from 2 pages
Interpretation boundary
What this record can and cannot establish
Inclusion in the registry is not endorsement. The record supports only the claims that fit its design, population, date, and scope. Company, media, and community records can document that a claim was made without proving the claim itself.